Skip to content

News releases

The following are news releases and statements issued by Biosimilars Canada. News stories about biosimilars that may be of interest to readers are available here.

Biosimilars Canada Announces Patient Support Program Platform

Biosimilars Canada, the national association representing Canada’s biosimilar medicines industry, today announced that Innomar Strategies, Canada's leading specialty pharmaceuticals service provider has been selected as the preferred provider for the Biosimilars Canada Patient Support Program (PSP) platform.
Read more

European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

Read more
Read more

Biosimilars Canada Statement on Revised Canadian Guidance for Sponsors of Biosimilars

The convergence of regulatory requirements is a top priority for sponsors of biosimilar medicines as single global development programs are typical given the high R&D costs for these complex products.
Read more

IGBA call for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

Read more
Read more

Canadian Generic Pharmaceutical Association Establishes First Voice for Biosimilars In Canada

The establishment of the new CGPA Biosimilars Board signifies the focus our industry is placing on ensuring that Canada is a viable market for the production and sale of biosimilar treatments.
Read more